Timothy Yap
Company: MD Anderson Cancer Center
Job title: Associate Professor, Investigational Cancer Therapeutics
Seminars:
Closing Panel Discussion: Future Directions for DDRi 5:30 pm
What is the current status of DDRi combination with IO Thoughts and rationalizing on potential best outcomes DDR-DDR combos Reviewing the various combination approaches and new targets coming in – thought experiment based on pathway What are the combinations and new targets that are going to push the field forward in a durable and effective…Read more
day: Day Two
Targeting ATR in the Clinic: Novel Agents and Rational Combinations 5:00 pm
• ATR inhibitors are a promising antitumor therapy • Patient selection is critical to optimize antitumor efficacy • Rational combinations will enhance the efficacy and reach of ATR inhibitorsRead more
day: Day Two
Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy? 2:20 pm
Analyzing the current applications of these inhibitors both in preclinical and clinical studies either as single agents or in combinations with chemotherapy, radiotherapy and immunotherapy Dissecting toxicity profiles (bone marrow toxicity?) Opening the ATR inhibitor black box: what clinical space will they occupy? Understanding biomarker indications for ATR sensitivity: Cyclin E, ATM Loss? not as…Read more
day: Day One
ATRi’s: Latest Clinical Trial Data 11:00 am